IP Library › Granted Patent US 6,846,841
Granted Patent B2
US 6,846,841 · App. 10/112,921 · Granted Jan 25, 2005

Anti-angiogenic compositions and methods of use

Assignee: Angiotech Pharmaceuticals, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,846,841
App. No.
10/112,921
Granted
Jan 25, 2005
Kind
B2
Abstract

The present invention provides compositions comprising an anti-angiogenic factor, and a polymeric carrier. Representative examples of anti-angiogenic factors include Anti-Invasive Factor, Retinoic acids and derivatives thereof, and paclitaxel. Also provided are methods for embolizing blood vessels, and eliminating biliary, urethral, esophageal, and tracheal/bronchial obstructions.

Claims (15)

1. A method for embolizing a blood vessel, comprising delivering into said vessel a therapeutically effective amount of a composition comprising a compound which disrupts microtubule function, wherein said compound is paclitaxel, or an analogue or derivative thereof, such that said blood vessel is effectively occluded.

2. The method according to claim 1 wherein said paclitaxel, or an analogue or derivative thereof is paclitaxel.

3. The method according to claim 1 or 2 wherein said composition further comprises a polymeric carrier.

4. The method according to claim 3 wherein said composition is formed into microspheres.

5. The method according to claim 3 wherein said polymeric carrier is poly(ethylene-vinyl acetate) crosslinked with 40% vinyl acetate.

6. The method according to claim 3 , wherein said polymeric carrier is poly(lactic-co-glycolic acid).

7. The method according to claim 3 wherein said polymeric carrier is poly(caprolactone).

8. The method according to claim 3 wherein said polymeric carrier is poly(lactic acid).

9. The method according to claim 3 wherein said polymeric carrier is a copolymer of poly(lactic acid) and poly(caprolactone).

10. The method according to claim 3 wherein said polymeric carrier is a copolymer of poly(ethylene-vinyl acetate) crosslinked with 40% vinyl acetate, and poly(lactic acid).

11. The method according to claim 1 or 2 wherein said blood vessel nourishes a tumor.

12. The method according to claim 1 or 2 wherein said blood vessel nourishes a non-tumorigenic, angiogenesis-dependent disease.

13. The method according to claim 3 wherein said blood vessel nourishes a tumor.

14. The method according to claim 3 wherein said blood vessel nourishes a non-tumorigenic, angiogenesis-dependent disease.

15. The method according to claim 3 wherein said polymeric carrier is biodegradable.

Assignments (16)
RELEASE OF SECURITY INTEREST : RECORDED AT REEL/FRAME - 049104/0392 Recorded Jan 29, 2021
From: CAPITAL ONE, NATIONAL ASSOCIATION
To: SURGICAL SPECIALTIES CORPORATION LIMITED
Reel/Frame 055171/0674 →
RELEASE OF SECURITY INTEREST : RECORDED AT REEL/FRAME - 049288/0184 Recorded Jan 29, 2021
From: CAPITAL ONE, NATIONAL ASSOCIATION
To: ANGIOTECH PHARMACEUTICALS, INC.
Reel/Frame 055171/0634 →
SECURITY INTEREST Recorded May 26, 2019
From: ANGIOTECH PHARMACEUTICALS, INC.
To: CAPITAL ONE, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT
Reel/Frame 049288/0184 →
SECURITY INTEREST Recorded May 7, 2019
From: SURGICAL SPECIALTIES CORPORATION LIMITED
To: CAPITAL ONE, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT
Reel/Frame 049104/0392 →
RELEASE OF SECURITY INTEREST Recorded May 7, 2019
From: VIRTUS GROUP, LP, AS ADMINISTRATIVE AGENT FOR THE LENDERS
To: SURGICAL SPECIALTIES CORPORATION LIMITED
Reel/Frame 049106/0173 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE ADDRESS PREVIOUSLY RECORDED ON REEL 042115 FRAME 0140. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Aug 8, 2017
From: ANGIOTECH PHARMACEUTICALS, INC.
To: SURGICAL SPECIALTIES CORPORATION LIMITED
Reel/Frame 043332/0360 →
PARTIAL RELEASE OF SECURITY INTEREST Recorded Apr 5, 2017
From: VIRTUS GROUP, LP
To: ANGIOTECH PHARMACEUTICALS, INC.
Reel/Frame 042166/0029 →
SECURITY INTEREST Recorded Apr 5, 2017
From: SURGICAL SPECIALTIES CORPORATION LIMITED
To: VIRTUS GROUP, LP
Reel/Frame 041860/0980 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 28, 2017
From: ANGIOTECH PHARMACEUTICALS, INC.
To: SURGICAL SPECIALTIES CORPORATION LIMITED
Reel/Frame 042115/0140 →
SECURITY INTEREST Recorded Mar 10, 2017
From: ANGIOTECH PHARMACEUTICALS, INC.
To: VIRTUS GROUP, LP
Reel/Frame 041539/0864 →
RELEASE OF SECURITY INTEREST Recorded Apr 12, 2013
From: WELLS FARGO CAPITAL FINANCE, LLC
To: ANGIOTECH PHARMACEUTICALS, INC.; AMERICAN MEDICAL INSTRUMENTS HOLDINGS, INC.; ANGIOTECH AMERICA, INC.; ANGIOTECH BIOCOATINGS CORP.; ANGIOTECH PHARMACEUTICALS (US), INC.; B.G. SULZLE, INC.; MANAN MEDICAL PRODUCTS, INC.; MEDICAL DEVICE TECHNOLOGIES, INC.; QUILL MEDICAL, INC.; SURGICAL SPECIALTIES CORPORATION; ANGIOTECH INTERNATIONAL HOLDINGS CORP.
Reel/Frame 030211/0479 →
PATENT SECURITY AGREEMENT Recorded May 13, 2011
From: ANGIOTECH PHARMACEUTICALS, INC.; AFMEDICA, INC.; AMERICAN MEDICAL INSTRUMENTS HOLDINGS, INC.; ANGIOTECH AMERICA, INC.; ANGIOTECH BIOCOATINGS CORP.; ANGIOTECH DELAWARE, INC.; ANGIOTECH FLORIDA HOLDINGS, INC.; ANGIOTECH PHARMACEUTICALS (US), INC.; B.G. SULZLE, INC.; MANAN MEDICAL PRODUCTS, INC.; MEDICAL DEVICE TECHNOLOGIES, INC.; NEUCOLL INC.; QUILL MEDICAL, INC.; SURGICAL SPECIALTIES CORPORATION; 0741693 BRITISH COLUMBIA LTD.; ANGIOTECH INTERNATIONAL HOLDINGS, CORP.
To: WELLS FARGO CAPITAL FINANCE, LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 026275/0507 →
SECURITY AGREEMENT Recorded Mar 2, 2009
From: ANGIOTECH PHARMACEUTICALS, INC.; AFMEDICA, INC.; AMERICAN MEDICAL INSTRUMENTS HOLDINGS, INC.; ANGIOTECH AMERICA, INC.; ANGIOTECH BIOCOATINGS CORP.; ANGIOTECH CAPITAL, LLC; ANGIOTECH PHARMACEUTICALS (US), INC.; B.G. SULZLE, INC.; CRIMSON CARDINAL CAPITAL, LLC; MANAN MEDICAL PRODUCTS, INC.; MEDICAL DEVICE TECHNOLOGIES, INC.; NEUCOLL INC.; QUILL MEDICAL, INC.; SURGICAL SPECIALTIES CORPORATION; 0741693 BRITISH COLUMBIA LTD.; 3091796 NOVA SCOTIA COMPANY; ANGIOTECH INTERNATIONAL HOLDINGS, CORP.; ANGIOTECH INVESTMENT PARTNERSHIP
To: WELLS FARGO FOOTHILL, LLC AS AGENT
Reel/Frame 022329/0310 →
CHANGE OF NAME Recorded Feb 5, 2009
From: ANGIOGENESIS TECHNOLOGIES, INC.
To: ANGIOTECH PHARMACEUTICALS, INC.
Reel/Frame 022203/0707 →
RELEASE OF SECURITY INTEREST Recorded Dec 11, 2006
From: CREDIT SUISSE
To: ANGIOTECH PHARMACEUTICALS, INC.
Reel/Frame 018606/0606 →
SECURITY AGREEMENT Recorded Apr 11, 2006
From: ANGIOTECH PHARMACEUTICALS, INC.
To: CREDIT SUISSE, AS COLLATERAL AGENT
Reel/Frame 017448/0692 →
Continuity (5)
Continuation 0901376500 · Jan 27, 1998
Continuation 0847891400 · Jun 7, 1995
Division 0841716000
Continuation In Part 0809453600 · Jul 19, 1993
Related Publication 20030004209A1 · Jan 2, 2003